TrialJapanese journal of clinical oncology2022

Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study.

Tadao Ishida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.